Michael Kauffman, CEO of Epix, said: “While PRX-00023 continued to show a highly desirable safety and tolerability profile, we are disappointed in the overall results observed in our recently completed Phase IIb trial in major depressive disorder. In light of these results, we have made the strategic decision to discontinue further development of this product candidate.”